Measurements, composite scores and the art of 'cutting-off'

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 787-790

  Machado, Pedro M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA; CLINICAL ASSESSMENT TOOL; COMPOSITE SCORE; DISEASE ACTIVITY IN PSORIATIC ARTHRITIS; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; GLOBAL RATING OF CHANGE; HUMAN; MEASUREMENT; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RHEUMATOLOGY; TREATMENT RESPONSE; YOUDEN INDEX; SPONDYLARTHRITIS;

ARTHRITIS, PSORIATIC; HUMANS; SPONDYLARTHRITIS;

EID: 84962191013     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208274     Document Type: Review

References (24)

1. Landewé RB, van der Heijde DM. Principles of assessment from a clinical perspective. Best Pract Res Clin Rheumatol 2003;17:365-79.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16.
4. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target:2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
5. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489-98.
6. Helliwell PS, Fitzgerald O, Mease PJ. Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012;39:398-403.
7. Her M, Kavanaugh A. A review of disease activity measures for psoriatic arthritis: what is the best approach? Expert Rev Clin Immunol 2014;10:1241-54.
8. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S64-85.
9. Machado PM, Raychaudhuri SP. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:711-28.
10. Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212-7.
11. Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the score. Ann Rheum Dis 2016;75:811-8.
12. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
13. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
14. Consolaro A, Ruperto N, Bracciolini G, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014;73:1380-3.
15. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000;45:23-41.
16. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 2010;19:539-49.
17. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010;63:737-45.
18. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 2000;6:39-49.
19. Turner D, Schünemann HJ, Griffith LE, et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010;63:28-36.
20. Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007;34:1188-93.
21. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62:965-9.
22. Helliwell PS, Coates LC. The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains? Ann Rheum Dis 2015;74:e66.
23. Schoels MM, Aletaha D, Smolen JS. Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. Ann Rheum Dis 2015;74:e67.
24. Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis 2016;75:640-3.